{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:38Z","timestamp":1790991638166,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.08.038","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T02:22:48Z","timestamp":1661134968000},"page":"5791-5797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["No significant increase in Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study"],"prefix":"10.1016","volume":"40","author":[{"given":"M.","family":"Jaffry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-2955","authenticated-orcid":false,"given":"F.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mandava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jagarlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jaffry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kornitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jedidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Souayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.vaccine.2022.08.038_b0005","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.08.038_b0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2377-13-195","article-title":"Guillain-Barre syndrome as a cause of acute flaccid paralysis in Iraqi children: a result of 15 years of nation-wide study","volume":"13","author":"Jasem","year":"2013","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.038_b0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.vaccine.2022.08.038_b0020","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2022.08.038_b0025","series-title":"Immunization safety review: influenza vaccines and neurological complications","author":"Stratton","year":"2004"},{"issue":"24","key":"10.1016\/j.vaccine.2022.08.038_b0030","first-page":"2465","article-title":"Influenza vaccination increased during the COVID-19 pandemic","volume":"326","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"issue":"41","key":"10.1016\/j.vaccine.2022.08.038_b0035","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.15585\/mmwr.mm7041a1","article-title":"Vaccination coverage by age 24 months among children born in 2017 and 2018 - National Immunization Survey-Child, United States, 2018\u20132020","volume":"70","author":"Hill","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.08.038_b0040","unstructured":"\u201cGBS (Guillain-Barr\u00e9 Syndrome) and Vaccines.\u201d Centers for Disease Control and Prevention, 25 Aug. 2021. Available from: https:\/\/www.cdc.gov\/vaccinesafety\/concerns\/guillain-barre-syndrome.html."},{"key":"10.1016\/j.vaccine.2022.08.038_b0045","doi-asserted-by":"crossref","unstructured":"Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 36, 123\u201333.","DOI":"10.1159\/000324710"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.038_b0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.038_b0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cid\/ciaa710","article-title":"Coronavirus disease 2019 pandemic: impact caused by school closure and national lockdown on pediatric visits and admissions for viral and nonviral infections-a time series analysis","volume":"72","author":"Angoulvant","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.038_b0060","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.vaccine.2010.09.020","article-title":"Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006\u20132009","volume":"29","author":"Souayah","year":"2011","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2022.08.038_b0065","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barre syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.08.038_b0070","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","article-title":"Guillain-Barre syndrome following influenza vaccination","volume":"292","author":"Haber","year":"2004","journal-title":"JAMA"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2022.08.038_b0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.410090707","article-title":"Guillain-Barre syndrome: its epidemiology and associations with influenza vaccination","volume":"9","author":"Schonberger","year":"1981","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.038_b0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2022.08.038_b0085","first-page":"295","article-title":"Guillain-Barre syndrome after administration of killed vaccines","volume":"39","author":"Schonberger","year":"1977","journal-title":"Dev Biol Stand"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.038_b0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000336113","article-title":"Guillain-Barre syndrome after H1N1 vaccination in the United States: a report using the CDC\/FDA Vaccine Adverse Event Reporting System (2009)","volume":"38","author":"Souayah","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.038_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CND.0b013e31824db14e","article-title":"Guillain-Barre syndrome after influenza vaccination in the United States, a report from the CDC\/FDA vaccine adverse event reporting system (1990\u20132009)","volume":"14","author":"Souayah","year":"2012","journal-title":"J Clin Neuromuscul Dis"},{"issue":"29","key":"10.1016\/j.vaccine.2022.08.038_b0100","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1016\/j.vaccine.2007.03.053","article-title":"Guillain-Barre syndrome after vaccination in United States a report from the CDC\/FDA vaccine adverse event reporting system","volume":"25","author":"Souayah","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.038_b0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jnnp.51.5.613","article-title":"A prospective study of acute idiopathic neuropathy. II. Antecedent events","volume":"51","author":"Winer","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.038_b0110","first-page":"288","article-title":"Guillain-Barre syndrome and influenza vaccines: current evidence","volume":"32","author":"Sanz Fadrique","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.vaccine.2022.08.038_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577719","article-title":"AstraZeneca COVID-19 vaccine and Guillain-Barre syndrome in Tasmania: a causal link?","volume":"360","author":"Oo","year":"2021","journal-title":"J Neuroimmunology"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.038_b0120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/20009666.2021.1954284","article-title":"A case of Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"11","author":"Rao","year":"2021","journal-title":"J Commun Hosp Intern Med Perspect"},{"key":"10.1016\/j.vaccine.2022.08.038_b0125","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011881","article-title":"Guillain-Barre syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality","author":"Marquez Loza","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2022.08.038_b0130","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e3286","article-title":"Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients","volume":"76","author":"Finsterer","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.038_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102207","article-title":"Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study","volume":"15","author":"Almufty","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"10269","key":"10.1016\/j.vaccine.2022.08.038_b0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.08.038_b0145","article-title":"Guillain-Barre syndrome following SARS-COVID-19 Infection: a case report from India","volume":"2021","author":"Singhai","year":"2021","journal-title":"Case Rep Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.038_b0150","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm10071428","article-title":"Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic","volume":"10","author":"Riad","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.038_b0155","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.038_b0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12020-020-02444-9","article-title":"Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review","volume":"70","author":"Lisco","year":"2020","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.038_b0165","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.dsx.2020.07.005","article-title":"Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review","volume":"14","author":"Zaki","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.vaccine.2022.08.038_b0170","doi-asserted-by":"crossref","unstructured":"Parohan M, et al. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 2020:1\u20139.","DOI":"10.1101\/2020.04.09.20056291"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.038_b0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3947\/ic.2021.0302","article-title":"COVID-19 vaccination for people with comorbidities","volume":"53","author":"Choi","year":"2021","journal-title":"Infect Chemother"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.038_b0180","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10900-020-00958-x","article-title":"COVID-19 vaccination hesitancy in the United States: a rapid national assessment","volume":"46","author":"Khubchandani","year":"2021","journal-title":"J Commun Health"},{"key":"10.1016\/j.vaccine.2022.08.038_b0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","article-title":"Vaccine hesitancy in the era of COVID-19","volume":"194","author":"Troiano","year":"2021","journal-title":"Public Health"},{"issue":"36","key":"10.1016\/j.vaccine.2022.08.038_b0190","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.038_b0195","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:04Z","timestamp":1759403764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22010258"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No significant increase in Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}